Accolade — Investor Presentation (October 2024)
38 slides from Accolade's investor presentation, October 2024
Slide 1: Accolade Inc. Investor Presentation
October 2024 NASDAQ: ACCD Accolade Inc. Investor Presentation
Slide 2: Forward-looking statements
This presentation contains “forward-looking statements” –that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such ‘‘anticipate,’’ ‘‘b
Slide 3: Building a customer-obsessed, nationwide healthcare delivery company
Building a customer-obsessed, nationwide healthcare delivery company 3
Slide 4: Investment Highlights
Investment Highlights Consistent revenue growth with increasing profitability Market leader in highly underpenetrated Personalized Healthcare market High revenue visibility and customer diversification Integrated platform enables scale, utilization, and margin expansion Massive opportunity to levera
Slide 5: What stands us apart
World-class Partner technology platform What stands us apart Broad customer Flywheel profile value 5
Slide 6: High Touch Healthcare Services Powered by Next Gen Technology
High Touch Healthcare Care Nurse Case Women’s Behavioral Nurses Health Health Advocates Managers Services Powered by Next Nurses Clinician Gen Technology Physicians (typically internal medicine or family practice) Panel of 1000+ Physician Our extraordinary care teams drive engagement, Specialists so
Slide 7: The Physician Gap impact is real
Delayed and deferred doctor visits The Physician Gap Fragmented communication impact is real between providers (episodes) Unnecessary surgeries and wrong treatments 7
Slide 8: We put doctors at the heart of the solution
We put doctors at the heart of the solution Physician-led Care Team Internal Physicians & Therapists Elite Specialists Expert Nurses Care Advocates Doctor-to-doctor Support Targeted outreach Single Point of Entry data sharing Benefits Verification of benefits ID card Claims and appeals Utilization m
Slide 9: Accolade fixes the Physician Gap
80% of visits occur same day Accolade fixes Data sharing with the Physician Gap outside physicians visit summaries and relevant data Overall savings: 4%+ EMO: 25% of surgeries cancelled, 85% care plans improved 9
Slide 10: Our World-Class Technology
Member Call Our Fingerprint Scheduling World-Class Technology Skills-Based Routing Automation We use technology and data to seamlessly give members trust and human connection, every time. TrueHealth AI Actions 10
Slide 11: Trust and human connection, every time
Trust and human connection, every time Member fingerprint Specific care team matching Integrated point True Health Actions solutions and care pathways 11
Slide 12: The future state is connected for ease
The future state is connected for ease Specialists Front door engagement Meds Pre-existing burdens Therapy SDOH Primary Care Benefits Point Solutions Lack of combined data timely Telehealth is used to form care High-risk member True Health Actions Urgent Actionable steps Care are given to member in
Slide 13: True Health Actions Drive Personalized Care Experience
True Health Actions Drive A Personalized Care Experience B A Concept – Member Health Snapshot B Deployed – Alerts C C Deployed – True Health Action Recommendations 13
Slide 14: True Health Actions Create a Personalized Digital Experience
True Health Actions Create a Personalized Digital Experience Accolade Driven user need “For you” Support call(s) to action (True Health Actions) Member Driven user need “Ways we can help” Bring User Need resolution paths to front 14
Slide 15: What AI means at Accolade
Artificial Intelligence A program and capabilities that can sense, reason, act, and adapt Machine Learning What AI means at Algorithms whose performance improve as they are exposed to more data over time Accolade Data Platform Foundational multi-layered data architecture that is the proprietary sour
Slide 16: Our AI capabilities and utilization
Our AI capabilities and utilization ▪ Interaction Monitoring ▪ Population Health ▪ Clinical Analytics ▪ Auto QA Evaluations ▪ Clinical Foundation Score ▪ Workforce Management Forecasting ▪ Auto Note Summarization ▪ EMO ML Models ▪ NPS and CSAT Sentiment ▪ Conversational AI across IVR ▪ Decision & Wo
Slide 17: Accolade's Advantages for the Healthcare Ecosystem
Accolade’s Advantages for the Healthcare Ecosystem Front Line Care Teams Data set End to end reporting 17
Slide 18: Today's Trusted Partner Ecosystem
Today’s Trusted Partner Ecosystem High-quality solutions, complementary to Accolade’s own, in categories that matter to our customers Musculoskeletal Diabetes, Weight, Metabolic Pharmacy Centers of Excellence Behavioral Health LGBTQIA+ Care Gastrointestinal Fertility Healthcare Wellness / Incentives
Slide 19: Driving appropriate use of customers' programs is core to our value proposition
Driving appropriate use of customers’ programs is core to our value proposition Ecosystem Programs Trusted Partner Ecosystem Existing point solutions Best-in-class solutions where customers enjoy easier purchasing and + implementation, enhanced features, and incremental utilization Benefit Warm site
Slide 20: Business Model Builds Momentum as Adoption Grows
Engage Partner Identify Business Model Builds Momentum as Adoption Grows ExpertM Route D Primary Care 20
Slide 21: Distribution Reach
Distribution Reach 21
Slide 22: Diversified customer profiles create opportunity and expand TAM
Diversified customer profiles create opportunity and expand TAM • Diversified across • Size • Industry • Enterprise, government, Broad customer profile health plan, consumer • Direct • Health Plan • Integrated • Consumer Multi-offering • Leverage investments • Ecosystem Partners Diversified channel
Slide 23: Business Model Builds Momentum as Adoption Grows
Business Model Builds Momentum as Adoption Grows Early and Repeat Expert Physicians Engagement Diagnosis & Treatment Review Member Insights and care recommendation 69% PCPs & Therapists Acute, Chronic & Preventive Ongoing data analysis Care team interaction and influence Registered Member Nurses Car
Slide 24: Improved Outcomes Across Conditions
Improved Outcomes Across Conditions No True One or more True Improvement Health Action Health Action Musculoskeletal AVOIDABLE ER VISITS 57% members engaged 44% received 1+ Interventions 15% 13% -13% Depression or Anxiety OUTPATIENT BH VISITS (per member per year) 47% members engaged 35% received 1+
Slide 25: Financials
Financials
Slide 26: Accelerating Accolade's Innovation
Accelerating Accolade’s Innovation Continuous investment in clinical transformation and operational excellence Created a Proven Launched Intelligent Launched Launched Mental Acquired 2nd.MD - Acquired PlushCare - Introduced High Touch, High Provider Matching Accolade COVID Health Integrated Expert M
Slide 27: Significantly Expanded Addressable Market $216 billion
Significantly Expanded Addressable Market $216 billion TAM 1400 Customers $170B 1200+ 1200 Primary Care 1000 800+ 800 $22B 600+ 600 Expert Medical Opinion 400 $24B 200 112 Navigation & Advocacy 54 20 0 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 (w M&A) 27
Slide 28: Consistent growth and progress toward profitability
Consistent growth and progress toward profitability $500 $460M - $475M $450 $414M $400 $363M $350 $310M $300 $250 $200 $170M $150 $133M $100 $50 $0 $15M-$20M (25%) (16%) (14%) (10%) (2%) ($50) FY20 FY21 FY22 FY23 FY24 FY25P Adj EBITDA Revenue 28 FYE = February
Slide 29: Customer and revenue diversification
Customer and revenue diversification FY24 1200+ customers FY20 ▪ No 5% customer in FY24 ▪ Broad industry diversification ▪ 54 customers ▪ 6 customers ~ 75% of revenue 29
Slide 30: Financial Targets and Goals (Non-GAAP)
Long-Term Goals Adj. Gross Margin 50-55% P&T as 13-17% Financial Targets and % of Rev. Goals Adj. Operating S&M as 15-20% (Non-GAAP) Expenses % of Rev. G&A as 7-9% % of Rev. Adj. EBITDA Margin 15-20% Refer to the Appendix for a reconciliation of these non-GAAP financial measures to the most 30 direc
Slide 31: Growth, Scale & Profitability
Growth, Scale & Profitability Highly diversified revenue mix Expanding margins and operating leverage One Accolade driving operational efficiencies Attractive and improving unit economics Clear vision toward $1B+ revenue and target financial model Accolade ©2023 31
Slide 32: Accolade
Accolade PERSONALIZED HEALTHCARE
Slide 33: Appendix
Appendix 33
Slide 34: Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA
Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA Adjusted Gross Profit is a non-GAAP financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization, and excluding stock-based compensation and severance costs. We define Adjus
Slide 35: Adjusted EBITDA (Loss) Reconciliation
Adjusted EBITDA (Loss) Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2020 2021 2022 2023 2024 Net Loss $ (51,365) $ (50,652) $ (123,124) $ (459,650) $ (99,805) Adjusted for: Interest expense (income), net 2,925 3,724 2,905 (255) (5,952) Income tax expense (benefit) 129 4 (5,639
Slide 36: Adjusted Gross Profit & Gross Margin Reconciliation
Adjusted Gross Profit & Gross Margin Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2020 2021 2022 2023 2024 Revenue $ 132,507 $ 170,358 $ 310,021 $ 363,142 $ 414,292 Cost of revenue, excluding depreciation and amortization (73,685) (93,673) (169,019) (198,905) (222,232) Amortiz
Slide 37: Adjusted Operating Expense Reconciliation
Adjusted Operating Expense Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2020 2021 2022 2023 2024 Revenue $ 132,507 $ 170,358 $ 310,021 $ 363,142 $ 414,292 Operating Expenses 107,026 123,462 266,727 627,751 306,513 Less: Depreciation and amortization (8,516) (8,212) (42,608) (4
Slide 38: Accolade
Accolade PERSONALIZED HEALTHCARE